Author:
Caponigro F.,Lorusso D.,Fornari G.,Barone C.,Merlano M.,Airoldi M.,Schena M.,MacArthur R.,Weitman S.,Jannuzzo M. G.,Crippa S.,Fiorentini F.,Petroccione A.,Comis S.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference14 articles.
1. Geroni C, Marchini S, Cozzi P et al (2002) Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res 62:2332–2336
2. Lockhart AC, Howard M, Hande KR et al (2004) A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res 10:468–475
3. Ten Tije AJ, Verweij J, Sparreboom A et al (2003) Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin Cancer Res 9:2957–2964
4. Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M (2003) Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 9:5402–5408
5. Simon R (1989) Optimal two-stage design for phase II clinical trials. Controll Clin Trials 10:1–10
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献